The market for oral anticoagulants has advanced significantly since warfarin was essentially the lone option. Still, in some cases, the use of improved direct oral anticoagulants (DOACs) can provoke ...

Overall, we have seen an increase in the use of dabigatran after the availability of idarucizumab. We should recognize, however, that we know that all 4 DOACs (direct oral anticoagulants) are ...

PHOENIX, AZ—Much like in the setting of acute ischemic stroke, shorter times to treatment are associated with better outcomes in patients with anticoagulation-associated intracerebral hemorrhage (ICH) ...

A novel anticoagulation system consisting of a factor IXa inhibitor and its reversal agent appears to be safe and feasible, effectively suppressing ischemic events during percutaneous coronary ...

NEW YORK, Jan. 14, 2025 /PRNewswire/ -- Report with market evolution powered by AI - The global anticoagulant reversal drugs market size is estimated to grow by USD 1.27 billion from 2025-2029, ...

Credit: Octapharma. Balfaxar is a human plasma-derived, purified, virus inactivated and nanofiltered non-activated prothrombin complex concentrate. Balfaxar ® (prothrombin complex concentrate, ...

Advances in new reversal agents will be key for managing patients treated with DOACs to prevent major bleeding events. Given these recent new guidelines, expert consensus statements, and multiple ...

SOUTH SAN FRANCISCO, Calif., Nov. 15, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that Annals of Emergency Medicine, the journal of the American College of ...

LEIDEN, The Netherlands--(BUSINESS WIRE)--VarmX, a clinical-stage biotech company focusing on development of innovative approaches for the reversal of anticoagulation, today announced treatment of the ...

CHICAGO — The Society of Thoracic Surgeons (STS), the Society of Cardiovascular Anesthesiologists (SCA), and the American Society of ExtraCorporeal Technology (AmSECT) have published the first ...

ORLANDO, Fla. — Andexanet alfa, a novel agent to reverse the effects of factor Xa inhibitors, demonstrated similar safety and efficacy outcomes to those seen with other reversal agents, according to ...

Michael B. Bottorff, PharmD: Fall risk is a major component of a discharge counseling strategy for patients who are newly being started on any anticoagulant, including a DOAC (direct oral ...